Moleculin's Annamycin Clears Cardiac Safety Hurdle in R/R AML Trials
Event summary
- Independent Cleveland Clinic review of 90 patients found no clinically significant cardiotoxicity with Annamycin, even beyond conventional anthracycline limits.
- Pooled analysis across 5 trials showed stable mean ejection fraction and no left ventricular dysfunction in R/R AML patients.
- Data presented at EHA 2026 Congress suggests Annamycin could address key barrier to anthracycline use in heavily pretreated patients.
- Moleculin's MIRACLE Phase 3 trial for Annamycin in R/R AML remains ongoing, with FDA feedback anticipated.
The big picture
Anthracyclines remain highly effective in AML but are limited by cardiotoxicity, particularly in relapsed/refractory patients with prior exposure. Moleculin's Annamycin aims to overcome this barrier, potentially expanding treatment options for heavily pretreated patients. The positive cardiac safety profile could position Annamycin as a differentiated therapy in an AML market where salvage options remain limited.
What we're watching
- Regulatory Pathway
- Whether the cardiac safety data will accelerate FDA review of Annamycin's Phase 3 MIRACLE trial.
- Market Positioning
- How Moleculin positions Annamycin against emerging venetoclax-resistant R/R AML treatments.
- Clinical Validation
- The pace at which additional cardiac safety data emerges from ongoing and future trials.
Related topics